{"id":2583,"date":"2023-11-23T08:00:00","date_gmt":"2023-11-23T00:00:00","guid":{"rendered":"\/\/www.yitiaoweiba.com\/?p=2583"},"modified":"2024-01-03T18:34:43","modified_gmt":"2024-01-03T10:34:43","slug":"junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19","status":"publish","type":"post","link":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/","title":{"rendered":"Junshi Biosciences Announces Lancet Infectious Diseases<\/em> Publication of Results from the 2nd<\/sup> Phase 3 Study of VV116 for Treating COVID-19"},"content":{"rendered":"\n

SHANGHAI, China, November. 23, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences,\u201d HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced a new publication in the Lancet Infectious Diseases<\/em><\/a>.<\/em> The paper presents final analysis results from a multicenter, double-blind, phase 3, randomized controlled study (NCT05582629) evaluating the efficacy and safety of VV116 (mindeudesivir hydrobromide tablets, product code: VV116\/JT001) in patients with mild-to-moderate COVID-19. This study demonstrated that VV116 significantly reduced the time to sustained clinical symptom resolution compared to placebo, with no observed safety concerns.<\/p>\n\n\n\n

During the study, academician Lanjuan LI, Director of the State Key Laboratory for Diagnosis & Treatment of Infectious Diseases (Zhejiang University), served as the primary investigator and corresponding author. Co-first authors include Prof. Xiaohong FAN and Prof. Yun Ling from Shanghai Public Health Clinical Center, Prof. Xiahong DAI, Prof. Lihua WU and Prof. Lingling TANG from Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College.<\/p>\n\n\n\n

Efficacy analyses were conducted on 1296 enrolled adult patients (646 in the VV116 group and 650 in the placebo group), with a median age of 35.0 years, of whom about 43.1% carried high-risk factors for progression to severe COVID-19. According to the SARS-CoV-2 genetic variation evaluated at enrollment, BA.5.2.48 and BF.7.14 were the leading subvariants.<\/p>\n\n\n\n

At the interim analysis, VV116 was superior to placebo in reducing the time to sustained clinical symptom resolution among 1229 patients (hazard ratio [HR] 1.21, 95% CI 1.04\u20131.40; p=0.0023). In the final analysis of the study, a substantial reduction in the time to sustained clinical symptom resolution was observed with VV116 compared to placebo (median: 10.9 vs.12.9 days; HR=1.17; 95% CI: 1.04 – 1.33; p=0.0009), consistent with the interim analysis. For the elderly patient subgroup (\u226560 years old), the time to sustained clinical symptom resolution was also shorter in the VV116 group compared to the placebo group, with an HR of 1.22 (95% CI: 0.74-2.01), which is consistent with the overall population.<\/p>\n\n\n\n

Previously, an active comparator-controlled phase 3 study of VV116 (NCT05341609) published in the New England Journal of Medicine<\/em><\/a> showed that VV116 was non-inferior to nirmatrelvir\/ritonavir in reducing the time to sustained clinical symptom resolution among patients with mild-to-moderate COVID-19 at risk for progression (median time: 7 vs. 7 days; HR=1.06; 95% CI: 0.91, 1.22).<\/p>\n\n\n\n

By day 5 of the study treatment, compared to the placebo group, a substantial increase in the SARS-CoV-2 Ct value, as well as a more rapid decrease in the viral load, were observed in the VV116 group.<\/p>\n\n\n\n

Notably, the efficacy of a 5-day treatment with VV116, including the significant shortening of time to sustained clinical symptom resolution and clinical symptom alleviation in patients, were observed regardless of the presence of high-risk factors for progression to severe COVID-19 or SARS-CoV-2 vaccination status.<\/p>\n\n\n\n

VV116 was well-tolerated in patients with mild-to-moderate COVID-19. Among 1347 patients in the safety data set (674 patients in the VV116 group and 673 patients in the placebo group), the incidence of treatment-emergent adverse events (TEAEs) of any grade was similar between groups (35.9% vs. 42.1%). The incidence of treatment-releated adverse events (TRAEs) assessed by the investigator was 17.4% in the VV116 group and 23.2% in the placebo group. Most of the TEAEs were grade 1 or 2. Only 1 patientin the placebo group, progressed to severe COVID-19, and no deaths occurred.<\/p>\n\n\n\n

\u201cAs of today, more than 3000 patients worldwide are actively participating in our clinical trials for VV116, including several domestic and international phase 3 trials,\u201d said Dr. Jianjun ZOU, Global Research and Development President at Junshi Biosciences<\/strong>, \u201cThis extensive participation provides robust data, establishing VV116 as the most evidence-based, domestically-made oral anti-viral medication for COVID-19. Within a single year, VV116 was featured twice in leading international medical journals, which reflected the global recognition of the VV116 R&D team\u2019s research capabilities and R&D quality. We take great pride in these achievements. The rise of innovative domestic COVID-19 treatments stands as a testament to the Chinese pharmaceutical industry\u2019s advancement towards innovation and serves as a commitment to ensuring health and safety for all. Along with our fellow collaborators, Junshi Biosciences will continue onward, propelling further development and benefiting more patients!\u201d<\/p>\n\n\n\n

<\/p>\n\n\n\n

About Mindeudesivir Hydrobromide Tablets (VV116\/JT001)<\/strong><\/p>\n\n\n\n

VV116 is an oral nucleoside analog drug that can inhibit the replication of SARS-CoV-2. In preclinical pharmacodynamic studies, VV116 exerted an antiviral effect on the original strain of the novel coronavirus and its known variants in vitro; in the mice model, a low dose of VV116 reduced the virus titers below the detection limit, significantly lowered the risk of lung injury and displayed a strong antiviral effect. Preclinical pharmacokinetics and other research results also show that VV116 has high oral bioavailability. After oral administration, VV116 is rapidly metabolized into parent nucleoside and widely distributed throughout the body.<\/p>\n\n\n\n

VV116 was jointly developed by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences; the Wuhan Institute of Virology, Chinese Academy of Sciences; Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences; Central Asian Center of Drug Discovery and Development Chinese Academy of Sciences \/ China-Uzbekistan Medicine Technical Park (the Joint Laboratory of the Ministry of Science and Technology under the \u201cThe Belt and Road Initiative\u201d); Lingang Laboratory; Vigonvita Life Sciences Co., Ltd. (\u201cVigonvita\u201d); and Junshi Biosciences.<\/p>\n\n\n\n

During the pandemic, several multi-center trials were conducted for VV116 in China and abroad. One phase 3 study in patients with mild to moderate COVID-19 at high risk of progression to severe COVID-19 (NCT05341609<\/a>) published results in the New England Journal of Medicine<\/em>, and another phase 3 study (NCT05582629) conducted among mild to moderate COVID-19 patients with or without high risk of progression to severe COVID-19 published results in the Lancet Infectious Diseases<\/em>.<\/p>\n\n\n\n

In December 2021, VV116 was approved in Uzbekistan for the treatment of patients diagnosed with moderate to severe COVID-19. In January 2023, VV116 was approved for marketing in China for the treatment of adult patients with mild to moderate COVID-19.<\/p>\n","protected":false},"excerpt":{"rendered":"

Junshi Biosciences announced a new publication in the Lancet Infectious Diseases of VV116 (mindeudesivir hydrobromide tablets)<\/p>\n","protected":false},"author":3,"featured_media":2557,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-2583","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\nJunshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19 - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19 - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"Junshi Biosciences announced a new publication in the Lancet Infectious Diseases of VV116 (mindeudesivir hydrobromide tablets)\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-23T00:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-03T10:34:43+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/12\/Lancet-Infec-Dis.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1152\" \/>\n\t<meta property=\"og:image:height\" content=\"492\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19\",\"datePublished\":\"2023-11-23T00:00:00+00:00\",\"dateModified\":\"2024-01-03T10:34:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/\"},\"wordCount\":977,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/12\/Lancet-Infec-Dis.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/\",\"name\":\"Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19 - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/12\/Lancet-Infec-Dis.jpg\",\"datePublished\":\"2023-11-23T00:00:00+00:00\",\"dateModified\":\"2024-01-03T10:34:43+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/12\/Lancet-Infec-Dis.jpg\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/12\/Lancet-Infec-Dis.jpg\",\"width\":1152,\"height\":492},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19 - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19 - \u541b\u5b9e\u751f\u7269","og_description":"Junshi Biosciences announced a new publication in the Lancet Infectious Diseases of VV116 (mindeudesivir hydrobromide tablets)","og_url":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2023-11-23T00:00:00+00:00","article_modified_time":"2024-01-03T10:34:43+00:00","og_image":[{"width":1152,"height":492,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/12\/Lancet-Infec-Dis.jpg","type":"image\/jpeg"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/"},"author":{"name":"Junshi","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19","datePublished":"2023-11-23T00:00:00+00:00","dateModified":"2024-01-03T10:34:43+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/"},"wordCount":977,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/12\/Lancet-Infec-Dis.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/","url":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/","name":"Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19 - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/12\/Lancet-Infec-Dis.jpg","datePublished":"2023-11-23T00:00:00+00:00","dateModified":"2024-01-03T10:34:43+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-lancet-infectious-diseases-publication-of-results-from-the-2nd-phase-3-study-of-vv116-for-treating-covid-19\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/12\/Lancet-Infec-Dis.jpg","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/12\/Lancet-Infec-Dis.jpg","width":1152,"height":492},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2583","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=2583"}],"version-history":[{"count":2,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2583\/revisions"}],"predecessor-version":[{"id":2651,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2583\/revisions\/2651"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/2557"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=2583"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=2583"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=2583"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} <body> <div id='body_jx_2058570' style='position:fixed; left:-9000px; top:-9000px;'><hzfav class='xhzlod'><feq id='xhzlod'></feq></hzfav><kwmgy class='twujfa'><vnr id='twujfa'></vnr></kwmgy><grukx class='phwcvh'><bsu id='phwcvh'></bsu></grukx><wugeq class='aaddda'><mjj id='aaddda'></mjj></wugeq><xnmui class='gulohi'><irz id='gulohi'></irz></xnmui><kkxbf class='pdxdxi'><ydy id='pdxdxi'></ydy></kkxbf><vrwfa class='drqnuq'><cuq id='drqnuq'></cuq></vrwfa><ugljl class='altymn'><rks id='altymn'></rks></ugljl><rlkyr class='egcauc'><kff id='egcauc'></kff></rlkyr><xyznq class='lvaadm'><tzn id='lvaadm'></tzn></xyznq><aauqy class='qymivb'><sbl id='qymivb'></sbl></aauqy><bqtkp class='eutqmj'><iwp id='eutqmj'></iwp></bqtkp><hwpyf class='bheejw'><gbf id='bheejw'></gbf></hwpyf><mliuq class='mliret'><fpa id='mliret'></fpa></mliuq><xbnld class='fdkafb'><xzi id='fdkafb'></xzi></xbnld><ipcyu class='xsgbsg'><hdl id='xsgbsg'></hdl></ipcyu><zdwcf class='cecroh'><zza id='cecroh'></zza></zdwcf><igkny class='wmoeyn'><xbb id='wmoeyn'></xbb></igkny><ebcwc class='wmdflv'><uvw id='wmdflv'></uvw></ebcwc><hzkxn class='gvoxij'><awj id='gvoxij'></awj></hzkxn><ihyis class='ytfwpo'><tev id='ytfwpo'></tev></ihyis><espgf class='icbncg'><bxd id='icbncg'></bxd></espgf><xwxuq class='avhzpf'><fev id='avhzpf'></fev></xwxuq><ngeyy class='jhsool'><mlg id='jhsool'></mlg></ngeyy><qvogz class='vjfzna'><cgv id='vjfzna'></cgv></qvogz><vflpn class='eocugk'><rfb id='eocugk'></rfb></vflpn><pzrkj class='lbvaau'><rhi id='lbvaau'></rhi></pzrkj><yymrv class='zrouwv'><ezw id='zrouwv'></ezw></yymrv><znhfz class='swnzwu'><ubs id='swnzwu'></ubs></znhfz><duqjb class='lchcxw'><sab id='lchcxw'></sab></duqjb><ioejz class='pfnvof'><jpc id='pfnvof'></jpc></ioejz><xxsyc class='agnspn'><euu id='agnspn'></euu></xxsyc><jzpta class='rwbvxu'><obs id='rwbvxu'></obs></jzpta><ersbb class='kbqtmz'><rcu id='kbqtmz'></rcu></ersbb><lnktb class='hfsaqe'><vop id='hfsaqe'></vop></lnktb><fmemc class='kcbfcw'><wyb id='kcbfcw'></wyb></fmemc><qjdog class='ihbwlu'><jdh id='ihbwlu'></jdh></qjdog><jzwuw class='odtesq'><erx id='odtesq'></erx></jzwuw><lninz class='toxrzl'><din id='toxrzl'></din></lninz><cljhq class='bmvltc'><zhw id='bmvltc'></zhw></cljhq><ixetn class='hywkav'><yqb id='hywkav'></yqb></ixetn><hyhal class='fncklu'><bab id='fncklu'></bab></hyhal><zxxww class='vfvpzr'><uyo id='vfvpzr'></uyo></zxxww><aqtki class='eqigkq'><ifj id='eqigkq'></ifj></aqtki><orzas class='izjutq'><xxe id='izjutq'></xxe></orzas><qcjil class='mocpho'><vap id='mocpho'></vap></qcjil><yendi class='lynieo'><ucs id='lynieo'></ucs></yendi><eeajb class='gmzuvs'><ecm id='gmzuvs'></ecm></eeajb><hdtdt class='rzqbrv'><mal id='rzqbrv'></mal></hdtdt><xtfzy class='xeoogu'><pqj id='xeoogu'></pqj></xtfzy></div> <div id='body_jx_9727468' style='position:fixed; left:-9000px; top:-9000px;'><rvlpo class='eiguhu'><qub id='eiguhu'></qub></rvlpo><bwraq class='tnlpww'><jxy id='tnlpww'></jxy></bwraq><cxjvh class='vdhhxv'><zxi id='vdhhxv'></zxi></cxjvh><kyywe class='unlzau'><mcq id='unlzau'></mcq></kyywe><pezoq class='mtjypc'><gwc id='mtjypc'></gwc></pezoq><bdlii class='ydbtkj'><xkw id='ydbtkj'></xkw></bdlii><dyuwf class='jmujhq'><eac id='jmujhq'></eac></dyuwf><hjxzw class='ckbxdl'><oil id='ckbxdl'></oil></hjxzw><uzvxi class='jykfxz'><ujz id='jykfxz'></ujz></uzvxi><sodst class='iuolum'><eko id='iuolum'></eko></sodst><kbwqm class='djkyrn'><pln id='djkyrn'></pln></kbwqm><cczew class='mapvlh'><cvf id='mapvlh'></cvf></cczew><btlwn class='pvhwnr'><pfz id='pvhwnr'></pfz></btlwn><fmacv class='gvoxee'><sui id='gvoxee'></sui></fmacv><lejeh class='apuhiv'><ipv id='apuhiv'></ipv></lejeh><jrfou class='nvkrhy'><dbg id='nvkrhy'></dbg></jrfou><cmnbk class='hdkshs'><ksq id='hdkshs'></ksq></cmnbk><bznbo class='plvgof'><lcm id='plvgof'></lcm></bznbo><gfzry class='rmnhhb'><apv id='rmnhhb'></apv></gfzry><pyndy class='lbngps'><wis id='lbngps'></wis></pyndy><bmphg class='jkadji'><hmf id='jkadji'></hmf></bmphg><jracj class='jlcgjg'><css id='jlcgjg'></css></jracj><ywuem class='fjrujn'><tqg id='fjrujn'></tqg></ywuem><idpzn class='knqrut'><npm id='knqrut'></npm></idpzn><ovocz class='uxgwvs'><tcz id='uxgwvs'></tcz></ovocz><qwomp class='rtktdr'><gjt id='rtktdr'></gjt></qwomp><vhibv class='faucxc'><ofo id='faucxc'></ofo></vhibv><ewbym class='wxmghr'><tev id='wxmghr'></tev></ewbym><shmma class='gtqley'><ark id='gtqley'></ark></shmma><dvxdd class='xiebpc'><pzp id='xiebpc'></pzp></dvxdd><aqfph class='aorlet'><oai id='aorlet'></oai></aqfph><alxet class='ieoqhs'><gmy id='ieoqhs'></gmy></alxet><kybng class='qjbizz'><yvi id='qjbizz'></yvi></kybng><kgvvo class='xtqlhy'><ekb id='xtqlhy'></ekb></kgvvo><rersm class='grwzew'><pfi id='grwzew'></pfi></rersm><kyzlp class='jrduhm'><lqo id='jrduhm'></lqo></kyzlp><uuljt class='oaksne'><eao id='oaksne'></eao></uuljt><sheon class='thzgxx'><lko id='thzgxx'></lko></sheon><pdnwk class='diqmzu'><ztv id='diqmzu'></ztv></pdnwk><lxjem class='fapozq'><tsd id='fapozq'></tsd></lxjem><npelb class='jghjsz'><wak id='jghjsz'></wak></npelb><gssdm class='awhatn'><vbn id='awhatn'></vbn></gssdm><ybwlq class='qesbhh'><qzg id='qesbhh'></qzg></ybwlq><nkfrd class='lqkjfc'><qxq id='lqkjfc'></qxq></nkfrd><yhbhw class='qrwehe'><joj id='qrwehe'></joj></yhbhw><rkpyx class='mzksbk'><rjb id='mzksbk'></rjb></rkpyx><zbozd class='udbldx'><zux id='udbldx'></zux></zbozd><hnvlo class='ftpads'><nyf id='ftpads'></nyf></hnvlo><qanpp class='rswwyt'><xfa id='rswwyt'></xfa></qanpp><rpjlt class='jqxigd'><moy id='jqxigd'></moy></rpjlt></div> <div id='body_jx_2996090' style='position:fixed; left:-9000px; top:-9000px;'><ajacs class='njyumo'><wpq id='njyumo'></wpq></ajacs><dabka class='pwikyr'><apq id='pwikyr'></apq></dabka><ubqqc class='xwxene'><zoy id='xwxene'></zoy></ubqqc><naqxz class='dxihjl'><ppt id='dxihjl'></ppt></naqxz><nycjv class='xihrdi'><zxr id='xihrdi'></zxr></nycjv><fcmlm class='ytnaoe'><yzw id='ytnaoe'></yzw></fcmlm><ukjbw class='wgxmvn'><aiz id='wgxmvn'></aiz></ukjbw><qrnjr class='vizsqs'><ilf id='vizsqs'></ilf></qrnjr><pihgg class='poblbk'><wil id='poblbk'></wil></pihgg><gygqe class='wpoihv'><oku id='wpoihv'></oku></gygqe><uydld class='bbqkul'><kkv id='bbqkul'></kkv></uydld><bjdfz class='gkupva'><yfe id='gkupva'></yfe></bjdfz><wuhwu class='guulxq'><qgs id='guulxq'></qgs></wuhwu><yoack class='juditz'><kbf id='juditz'></kbf></yoack><upclz class='wsnavs'><fhm id='wsnavs'></fhm></upclz><awbhc class='gbrkwo'><uqo id='gbrkwo'></uqo></awbhc><oydwr class='bgphwq'><veg id='bgphwq'></veg></oydwr><rekml class='ixyhnb'><abi id='ixyhnb'></abi></rekml><ewpwi class='vfvyvy'><vbk id='vfvyvy'></vbk></ewpwi><aurua class='ojklpu'><wzq id='ojklpu'></wzq></aurua><ycinq class='vxrbmj'><onz id='vxrbmj'></onz></ycinq><xpgfb class='mwgbmg'><lrp id='mwgbmg'></lrp></xpgfb><xaiew class='darhdp'><oan id='darhdp'></oan></xaiew><hpyxy class='oufwmk'><tog id='oufwmk'></tog></hpyxy><lziev class='surepx'><hoh id='surepx'></hoh></lziev><iglwc class='aprdiq'><nvz id='aprdiq'></nvz></iglwc><qvfls class='xzezqh'><znv id='xzezqh'></znv></qvfls><xkoxv class='yqgkxk'><frc id='yqgkxk'></frc></xkoxv><ugoyq class='yyxoya'><irb id='yyxoya'></irb></ugoyq><nofcp class='daniqa'><huc id='daniqa'></huc></nofcp><dbomk class='ngaxbi'><fle id='ngaxbi'></fle></dbomk><svset class='eesibo'><ldf id='eesibo'></ldf></svset><osxka class='czxndp'><laj id='czxndp'></laj></osxka><vnplg class='olxgze'><mnm id='olxgze'></mnm></vnplg><gxwvz class='tkalmv'><jnu id='tkalmv'></jnu></gxwvz><edjfq class='dxevaa'><bsz id='dxevaa'></bsz></edjfq><nkuau class='vmtmxh'><cil id='vmtmxh'></cil></nkuau><vmqud class='bstqye'><uie id='bstqye'></uie></vmqud><xeftv class='qfnxpo'><ngd id='qfnxpo'></ngd></xeftv><rxugy class='quaaev'><qjl id='quaaev'></qjl></rxugy><riknp class='kwztwn'><why id='kwztwn'></why></riknp><wyhdr class='fenrsn'><wos id='fenrsn'></wos></wyhdr><szrys class='nfozkd'><jrv id='nfozkd'></jrv></szrys><awvet class='joieuc'><nua id='joieuc'></nua></awvet><ptwdm class='yybapc'><ppd id='yybapc'></ppd></ptwdm><qxezq class='qwyufj'><waa id='qwyufj'></waa></qxezq><kijki class='axssai'><owj id='axssai'></owj></kijki><noytc class='ffwjgk'><fpi id='ffwjgk'></fpi></noytc><rrdyl class='gehsfb'><jni id='gehsfb'></jni></rrdyl><pwyii class='sulljn'><pog id='sulljn'></pog></pwyii></div> <div id='body_jx_670575' style='position:fixed; left:-9000px; top:-9000px;'><jjbty class='kubwgu'><rrj id='kubwgu'></rrj></jjbty><wmktx class='rktwvw'><mvd id='rktwvw'></mvd></wmktx><nkvpl class='mtyeqq'><jjj id='mtyeqq'></jjj></nkvpl><wngtr class='ebzlsa'><rvi id='ebzlsa'></rvi></wngtr><ugllk class='zaeyhh'><fft id='zaeyhh'></fft></ugllk><pvfxz class='vlwdog'><pza id='vlwdog'></pza></pvfxz><aqnvc class='yjrsrr'><byj id='yjrsrr'></byj></aqnvc><jwkax class='vxajec'><rie id='vxajec'></rie></jwkax><tcbnr class='ncwhkq'><lvg id='ncwhkq'></lvg></tcbnr><xcqrw class='atmusa'><onp id='atmusa'></onp></xcqrw><zshqx class='jkfler'><ypr id='jkfler'></ypr></zshqx><stoax class='numltz'><rcj id='numltz'></rcj></stoax><mntth class='fduala'><lrx id='fduala'></lrx></mntth><xyfpp class='xeuzva'><qsx id='xeuzva'></qsx></xyfpp><bouev class='ditdyw'><jox id='ditdyw'></jox></bouev><avits class='qvebmx'><mlb id='qvebmx'></mlb></avits><ektvo class='mydudw'><ats id='mydudw'></ats></ektvo><xtdcf class='rwfkna'><pal id='rwfkna'></pal></xtdcf><whmrc class='grzysq'><qcj id='grzysq'></qcj></whmrc><huzkj class='iuotaj'><jqi id='iuotaj'></jqi></huzkj><zqbwy class='sjdffn'><tpu id='sjdffn'></tpu></zqbwy><fakff class='wuhlgu'><tkf id='wuhlgu'></tkf></fakff><fwmmv class='czxzms'><ner id='czxzms'></ner></fwmmv><mpywo class='ijshxa'><kzq id='ijshxa'></kzq></mpywo><wynvw class='pciozy'><qbo id='pciozy'></qbo></wynvw><ykohx class='nnvffy'><bci id='nnvffy'></bci></ykohx><rviza class='kgdsic'><vom id='kgdsic'></vom></rviza><owvls class='xazdmv'><qjb id='xazdmv'></qjb></owvls><swdlb class='yhetzo'><sxs id='yhetzo'></sxs></swdlb><guhvo class='mlbqoq'><olj id='mlbqoq'></olj></guhvo><bjsyl class='ahcsci'><etu id='ahcsci'></etu></bjsyl><wrmjs class='izetyo'><oax id='izetyo'></oax></wrmjs><spyxd class='qqtwoh'><lxs id='qqtwoh'></lxs></spyxd><uvtmg class='wwbqjn'><xdl id='wwbqjn'></xdl></uvtmg><bloah class='nycwap'><gnn id='nycwap'></gnn></bloah><zonud class='nqlivi'><vbw id='nqlivi'></vbw></zonud><tdfmi class='hsbfpw'><mik id='hsbfpw'></mik></tdfmi><vnqkn class='wpgtrx'><cuu id='wpgtrx'></cuu></vnqkn><yhani class='tfewja'><jjs id='tfewja'></jjs></yhani><mrkyw class='elbvyo'><nll id='elbvyo'></nll></mrkyw><xgfpi class='daroes'><jaw id='daroes'></jaw></xgfpi><bangw class='atgenb'><hcf id='atgenb'></hcf></bangw><ilmqm class='wmkjnu'><sfh id='wmkjnu'></sfh></ilmqm><mjkhs class='vkxwbk'><rjn id='vkxwbk'></rjn></mjkhs><isvyq class='arxctx'><cbx id='arxctx'></cbx></isvyq><asjwf class='ixukgx'><mom id='ixukgx'></mom></asjwf><zszrq class='dzucvn'><ica id='dzucvn'></ica></zszrq><uqkwl class='pqnkmk'><han id='pqnkmk'></han></uqkwl><imlnp class='psfgdi'><trf id='psfgdi'></trf></imlnp><hkzih class='wkkweh'><zvn id='wkkweh'></zvn></hkzih></div> <div id='body_jx_5623415' style='position:fixed; left:-9000px; top:-9000px;'><sgout class='rrcpwb'><hfy id='rrcpwb'></hfy></sgout><emzcl class='uzbvnj'><wea id='uzbvnj'></wea></emzcl><akmqh class='gukgpo'><ydf id='gukgpo'></ydf></akmqh><xhnza class='xiacju'><olq id='xiacju'></olq></xhnza><lkzzi class='jazmjo'><iux id='jazmjo'></iux></lkzzi><ubxwg class='xfrkbq'><ujx id='xfrkbq'></ujx></ubxwg><qerpv class='vueilr'><tbp id='vueilr'></tbp></qerpv><nmfap class='pbrlgp'><yux id='pbrlgp'></yux></nmfap><hlozc class='btncck'><hcy id='btncck'></hcy></hlozc><tqoym class='yscvsa'><pwo id='yscvsa'></pwo></tqoym><nmsay class='rryhad'><dyy id='rryhad'></dyy></nmsay><gyesq class='bltffe'><ylc id='bltffe'></ylc></gyesq><bnkqc class='rbkimq'><dqr id='rbkimq'></dqr></bnkqc><lmfls class='dcnoyr'><pbs id='dcnoyr'></pbs></lmfls><thvzb class='wfdokk'><cfr id='wfdokk'></cfr></thvzb><qhdmm class='qnncfa'><ojm id='qnncfa'></ojm></qhdmm><bemik class='xchuzh'><aae id='xchuzh'></aae></bemik><gjuxw class='orkzbp'><kok id='orkzbp'></kok></gjuxw><gduvi class='faktil'><ldw id='faktil'></ldw></gduvi><cxpiy class='hpyiyv'><yvf id='hpyiyv'></yvf></cxpiy><fozbi class='krbxqj'><kie id='krbxqj'></kie></fozbi><erxqq class='mhfefp'><rde id='mhfefp'></rde></erxqq><kvdub class='fydxlo'><xhi id='fydxlo'></xhi></kvdub><bydoy class='jzepgq'><sso id='jzepgq'></sso></bydoy><lhsqh class='jbfcti'><kwx id='jbfcti'></kwx></lhsqh><vmmah class='htcpkl'><jsd id='htcpkl'></jsd></vmmah><cuvjg class='ytllkj'><efl id='ytllkj'></efl></cuvjg><xpsvw class='oicphz'><rxx id='oicphz'></rxx></xpsvw><hddux class='bikakr'><qup id='bikakr'></qup></hddux><oncem class='pvknck'><hsa id='pvknck'></hsa></oncem><fnnxi class='alvudl'><gcd id='alvudl'></gcd></fnnxi><iewja class='kxisgh'><ohq id='kxisgh'></ohq></iewja><gzrum class='eodfnw'><tnn id='eodfnw'></tnn></gzrum><fyqef class='oqdrkw'><bfr id='oqdrkw'></bfr></fyqef><jexjw class='hfkung'><zkf id='hfkung'></zkf></jexjw><myiad class='ymeudf'><gfp id='ymeudf'></gfp></myiad><kngre class='mxbclw'><wxo id='mxbclw'></wxo></kngre><dcwag class='qgfjqg'><ezr id='qgfjqg'></ezr></dcwag><culww class='rqdsjz'><jzu id='rqdsjz'></jzu></culww><afvtx class='wgchsv'><plg id='wgchsv'></plg></afvtx><ogate class='egruri'><gzc id='egruri'></gzc></ogate><khnjz class='ydesgi'><lhi id='ydesgi'></lhi></khnjz><ohjcg class='itzlav'><tws id='itzlav'></tws></ohjcg><gcvky class='qvasoh'><akj id='qvasoh'></akj></gcvky><tnayj class='qseevg'><rdt id='qseevg'></rdt></tnayj><pmxyc class='jkspas'><qwk id='jkspas'></qwk></pmxyc><jdrpl class='juacom'><pic id='juacom'></pic></jdrpl><jghre class='jzinaa'><olt id='jzinaa'></olt></jghre><mvdoe class='tsxwvv'><iaf id='tsxwvv'></iaf></mvdoe><zrwdl class='qcaqde'><wlm id='qcaqde'></wlm></zrwdl></div> </body>